Background. Older adults with depression have an increased risk of developing dementia. Low plasma beta-amyloid 42 (A β 42) and A β 42/A β 40 have emerged as promising biomarkers of dementia. The association between depression and plasma A β is unclear.
D
EPRESSION in older adults is associated with an increased risk of cognitive decline, dementia, and mild cognitive impairment ( 1 , 2 ) . Although the mechanisms are not fully understood, it has been shown that a history of depression is associated with increased development of amyloid plaques and neurofi brillary tangles -two hallmarks of Alzheimer ' s disease (AD; 3 -5 ) .
Several studies have indicated that there may be a relationship between plasma A β 42 and A β 42/A β 40 and depression, but these results have been inconclusive ( 6 -8 ) . For example, an association between high plasma A β 40/A β 42 (consistent with low A β 42/A β 40) and increased risk of depression has been reported ( 8 ) . Whereas low plasma A β 42 has also been associated with an increased risk for depression ( 5 , 9 ) , others have reported a negative association ( 6 , 7 ) . One cross-sectional study also reported an interaction between A β , depression, and a polipoprotein E (APOE) e4 allele status, a major genetic risk factor for AD ( 9 ) . Plasma A β 42 and A β 42/A β 40 have previously been shown to be promising biomarkers for cognitive decline and AD; this is of interest because the plasma levels appear to fl uctuate in parallel with cerebrospinal fl uid levels but are obtained in a much less invasive manner ( 10 -12 ) .
As prior studies have been inconclusive and limited by small sample size and cross-sectional design, we sought to prospectively investigate the association between plasma A β 42 and A β 42/A β 40 and incident depression in a large cohort of older adults. A second objective was to determine if APOE e4 allele status modifi ed the association between A β level and depression. We hypothesized that those with low A β 42 and A β 42/A β 40 would have increased risk for depression and that these associations would be stronger among those with at least one APOE e4 allele.
M ethods

Study Population
Participants were enrolled in the ongoing Health Aging and Body Composition (Health ABC) study. This prospective cohort of 3,075 community-dwelling white and black older adults began in 1997. At baseline, participants were 70 -79 years of age and lived in Memphis, Tennessee, or Pittsburgh, Pennsylvania. Participants were recruited from a random sample of Medicare eligible adults living within designated zip codes and were eligible if they reported no diffi culties performing activities of daily living, walking a quarter mile, or climbing 10 steps without resting. They also had to be free of life-threatening cancers and plan to remain within the study area for at least 3 years ( 13 ) .
From the original cohort, a random sample of 999 sexand race-stratifi ed Health ABC participants who had baseline and at least one other cognitive measure over time had plasma A β 42 and A β 40 measured from stored plasma at Year 2. Our analytic cohort consisted of 988 participants with plasma A β measured and who had baseline plus at least one other depression measure over time. All participants included in this analytic cohort were free of cognitive impairment at baseline; consistent with previous literature, cognitive impairment was defi ned as a Modifi ed Mini-Mental Status Exam (3MS) score more than 80 ( 14 ) .
Standard Protocol Approvals, Registrations, and Patient Consents
This study was approved by the institutional review boards of the University of Pittsburgh and the University of Tennessee, Memphis, and that of the coordinating center, the University of California San Francisco. All participants signed a written informed consent.
Beta Amyloid
Stored plasma obtained in Year 2 of Health ABC was used to measure A β 40 and A β 42. Plasma was stored at − 70°C at Fisher BioServices, Inc. Laboratories and shipped directly to the analytical laboratory. Plasma A β was measured at the laboratory of Dr. Steven Younkin at the Mayo Clinic using Innogenetics INNO-BIA assays ( 12 ) . The detection limit for this assay is 12 pg/m L for A β 40 and 5 pg/m L for A β 42. Mean inter-assay coeffi cient of variation was 9.9% for A β 40 and 9.3% for A β 42 , and mean intra-assay coeffi cient of variation was 3.5% for A β 40 and 2.3% for A β 42. We categorized A β 42 and A β 42/A β 40 into " low, " " medium, " and " high " tertile groups, consistent with our previous study investigating plasma A β and cognitive decline among older adults ( 12 ) .
Depression
The full 20-item Center for Epidemiologic StudiesDepression Scale (CES-D) was used to assess depressive symptoms at baseline, with scores for the CES-D-10 calculated. The CES-D-10 was used to assess depressive symptoms within the previous week at all follow-up visits (Years 3, 5, 8 , and 10) ( 15 ) . The 10-item version is a shortened version of the original 20-item scale, has been widely used in older populations, and has good validity and reliability ( 15 , 16 ) . The shortened scale ranges from 0 to 30 and has good predictive accuracy when compared with the original 20-item scale ( 17 ) . Previous literature has shown that clinically signifi cant depressive symptoms are indicated by a score more than or equal to 10, which for the purposes of this manuscript will be referred to as depression ( 17 , 18 ) . Incident depression over 9 years was defi ned as the fi rst occurrence of depression from Year s 1 to 10 (a score of ≥ 10).
Covariates
At baseline, demographic information gathered from participants included age, race, sex , and education. Prevalent disease algorithms based on both self-report and physician diagnoses, recorded medications and laboratory data were used to create comorbidity variables indicating presence of diabetes mellitus, hypertension, stroke or transient ischemic attack, and myocardial infarction. Body mass index (kg/m 2 ) was calculated from direct height and weight measurements at baseline. Global cognitive function was measured with the 3MS. Incident dementia was defi ned as a self-reported previous diagnosis of dementia from a physician or prescription of any medication used to treat the symptoms of dementia, including: Aricept, Galantamine (Razadyne), Rivastigmine (Exelon), Memantine (Namenda), and Tacrine. Cystatin C was measured using baseline plasma stored at − 70°C at the Health ABC core laboratory (University of Vermont, Burlington), using a BNII nephelometer (Dade Behring, Deerfi eld, Illinois), which used a particle-enhanced immunonepholometric assay (N Latex Cystatin C; 19 ) . APOE e4 allele status was determined using standard s ingle -n ucleotide p olymorphism genotyping techniques and dichotomized into having at least one APOE e4 allele versus having no APOE e4 allele ( 20 ) .
Statistical Analyses
Pearson chi-square and analysis of variance tests were used, as appropriate, to determine the association between A β 42 and A β 42/A β 40 tertile and baseline participant characteristics and depression at baseline. After excluding the 51 participants who had depression at baseline, unadjusted high tertile had depression. As the interaction between A β 42/A β 40 and APOE e4 ( χ 2 = 9.08, df = 1, p = .003) was signifi cant, models were stratifi ed by APOE e4 allele status. There was no signifi cant association between A β 42/A β 40 and depression at baseline among those with (low 1.8% vs medium 2.8%, vs high 1.4%; χ 2 = 1.48, df = 2, p = .48) or without (low 0.77% vs medium 1.7%, vs high 2.2%; χ 2 = 2.68, df = 2, p = .26) an e4 allele; results for A β 42 were similar (data not shown).
Over 9 years, 220 (23.5%) participants who did not have depression at baseline developed incident depression; this included 93 participants in Year 3 (9.9%), 67 participants in Year 5 (7.2%), 39 participants in Year 8 (4.3%) , and 21 participants in Year 10 (2.2%). In unadjusted Cox proportional hazards models, stratifi ed by APOE e4, those with a low ratio and an e4 allele had an increased risk of depression over time (low n = 34 [ 10.8% ] vs high n = 10 [ 3.2% ] , hazard ratio [ HR ] = 2.14, df = 1, 95% confi dence interval [ CI ] : 1.06 -4.34) as compared with those with a high ratio ( Figure 1 ). These results remained signifi cant after adjustment for race, education, diabetes, and baseline 3MS ( Table 2 ) . Conversely, among those without an e4 allele, there was no association between low A β 42/A β 40 and depression, compared to those with high A β 42/A β 40 in unadjusted ( Figure 1 Table 2 ). There was no Cox proportional hazards models were used to determine the association between A β 42 and A β 42/A β 40 and risk of incident depression over time. In order to determine if APOE e4 allele status modifi ed the association between A β 42 or A β 42/A β 40 and depression, we assessed for an interaction, and if the interaction term was signifi cant ( p < .05), we stratifi ed the models by APOE e4. Low, medium , and high tertile of A β 42/A β 40 (also A β 42) were compared with the highest tertile as the reference group. Models were also adjusted by all baseline characteristics that were signifi cantly associated with A β level at baseline ( p ≤ .10), including race, education, diabetes, and baseline 3MS. In order to determine if the association between A β 42/A β 40 and depression was independent of an association between A β 42/ A β 40 and dementia, sensitivity analyses were performed after excluding 153 participants who developed incident dementia over the study period. All statistical analyses were performed using SAS version 9.1 (SAS Institute Inc., Cary, North Carolina).
R esults
The mean age at baseline of the 988 participants was 74.0 ± 3.0 years, 545 participants (55.2%) were women , 531 (53.7%) were black, 51 (5.2%) had depression, and 286 (28.9%) had one or more e4 allele. The mean ( ± SD ) and median plasma A β 42 were 33.9 ± 9.7 and 32.83 pg/m L , respectively , and for A β 42/A β 40 were 0.19 ± 0.07 and 0.18 pg/mL . At baseline, participants in the low A β 42/A β 40 tertile were more likely to be black ( χ 2 = 9.98, df = 2, p = .007), to have diabetes ( χ 2 = 6.06, df = 2, p = .05), and to have one or more e4 allele ( χ 2 = 17.37, df = 2, p < .001 ; Table 1 ). Similar patterns were observed for A β 42 (data not shown).
At baseline, 12 (3.7%) participants in the low A β 42/ A β 40 tertile, 20 (6.0%) in the medium , and 19 (5.8%) in the signifi cant association between A β 42 and depression over 9 years in either e4 group (data not shown).
Over the study period, 153 (16.3%) participants developed incident dementia and were excluded in sensitivity analyses. In unadjusted Cox proportional hazards models, stratifi ed by APOE e4, those with a low ratio and an e4 allele had an increased risk of depression over time (low n = 23 
D iscussion
In this prospective cohort study of white and black community-dwelling older adults, those with low A β 42/ A β 40 and an APOE e4 allele had an increased risk for depression over 9 years; this relationship was not observed for those with low A β 42/A β 40 and no e4 allele. This association remained even after excluding participants who developed incident dementia over the study period, indicating that circulating A β levels in the periphery may contribute to the pathogenesis of both depression and AD but that they are independent of each other. In another recent Health ABC study, older adults with low plasma A β 42/A β 40 were also at an increased risk for cognitive decline over time ( 12 ) . Together, these results suggest that older adults with low plasma A β 42/A β 40 and an APOE e4 allele are likely at an increased risk for both depression and AD.
These results are consistent with previous studies showing those with high A β 40/A β 42 (consistent with low A β 42/ A β 40) have an increased risk of depression ( 8 , 9 ) . They further add to existing literature in demonstrating that APOE e4 allele status modifi es the association between plasma A β 42/A β 40 and depression. It has been suggested that such an interaction may refl ect the presence of a subtype of depression that is a prodromal form of AD ( 9 ) . For example, one cross-sectional study of homebound older adults with no APOE e4 allele found those with depression had lower plasma A β 42, higher A β 40/A β 42, and poorer performance on cognitive tests than those without depression ( 9 ) . Conversely, older adults with an APOE e4 allele had lower plasma A β 42 and higher A β 40/A β 42 than older adults without an APOE e4 allele, regardless of depression status ( 9 ) . Our results differed from previous studies in that we found no association between A β 42 or and depression in older adults at baseline or over time, even after stratifying by APOE e4 allele and excluding those with incident dementia ( 9 ) . The difference in fi ndings could be due to the cross-sectional nature of the previous studies; differences may also exist due to different study populations (community dwelling with no major functional impairment in Health ABC, compared with homebound older adults in the previous studies; 8 , 9 ) . The hypothesis that depression associated with low plasma A β 42/A β 40 may represent prodromal dementia postulates that depression in older adults has various pathologies and etiologies, and depression occurring in the earliest preclinical phases of dementia is a particular subtype ( 8 , 9 ) . It has been suggested that plasma A β 42/A β 40 may be a marker of this subtype of depression because of the previously described associations between plasma A β 42/A β 40 and dementia and between plasma A β 42/A β 40 and depression ( 8 , 10 , 12 , 21 ) Because having an APOE e4 allele is a risk factor for AD, this theory is strengthened if those with APOE e4 allele status have a stronger association between A β and depression. Our results support the hypothesis that among those with at least one APOE e4 allele, low A β 42/ A β 40 is associated with an increased risk of depression and that this depression could be prodromal dementia. This fi nding is noteworthy because distinguishing the prodromal dementia subtype of depression from other depression in older adults may allow for earlier intervention or cognitive training in those at an increased risk for dementia. However, it also important to note that our results remained signifi cant even after excluding those with incident dementia, indicating that although depression and dementia may have a common underlying pathway, A β 42/A β 40 likely exerts some independent effects on depression.
There are several possible mechanisms underlying the association of A β 42/A β 40 and depression. For example, high plasma A β 40/A β 42 (consistent with low A β 42/A β 40) has been associated with amygdala atrophy and decreased total brain volume; both the amygdala and brain volume are implicated in depression and dementia ( 5 ) . Another possible mechanism underlying the relationship between depression and A β 42/A β 40 is the development of amyloid plaques. Although amyloid plaques are a hallmark of AD ( 22 , 23 ) , a lifetime history of depression has also been linked with the formation of amyloid plaques in the medial temporal lobe ( 4 ) . This evidence would further support the idea that an association between plasma A β 42/A β 40 and depression is indicative of a prodromal dementia subtype of depression. There are other possible mechanisms underlying the association between depression and plasma A β 42/A β 40 that are not directly dementia related, such as hippocampal atrophy ( 5 , 24 ) . To explain, it has been reported that high A β 40/ A β 42 (consistent with low A β 42/A β 40) may be related to increased hippocampal atrophy, which in turn is related to increased risk of depression ( 5 , 25 ) . Another possible underlying mechanism is stress; chronic stress has been shown to be associated with both depression and increased glucocorticoid levels ( 24 , 26 ) . In animal models, chronic glucocorticoid administration was also associated with an increased plasma A β 42/A β 40 level, but future studies are needed to investigate if there is also a relationship in humans ( 27 ) . Finally, another potential mechanism is a shared genetic risk for depression and AD, possibly indicated by APOE e4 status; at least one longitudinal study of older men found that depression is associated with an increased risk of dementia but only among those with APOE e4 ( 24 , 28 ) .
This study has several strengths including a prospective study design and a relatively large sample size. Furthermore, depression was measured at multiple time points, and we were able to adjust for a large number of potential confounders. We also repeated analyses including those who were taking an antidepressant medication but who did not have a score consistent with depression on the CES-D-10, and this did not signifi cantly change our results. Furthermore, as Health ABC also had the Geriatric Depression Scale measured at one study visit, we performed sensitivity analyses to see if the association changed for those with depression on this scale, but again, results did not signifi cantly change. Another strength is that Health ABC consists of community-dwelling older adults who were fairly high functioning and likely dementia free at baseline. Because of detailed follow-up data , we were able to exclude participants who developed incident dementia over the 9-year study period, and this is another strength. Finally, Innogenetics INNO-BIA assays were used to measure A β 42 and A β 40, which may provide more accurate measurements of these plasma markers than enzyme-linked immunosorbent assays because of the high sensitivity, low variability, and high reproducibility ( 29 ) .
There are also several weaknesses that should be taken into consideration when interpreting these results. For example, the CES-D-10 measures self-reported depressive symptoms and is not a diagnostic assessment of depression ( 15 ) . Another weakness is that we only had depressive symptoms measured at discrete study visit time points and did not have information on whether or not depressive symptoms were experienced at times between study visits. Thus, if participants had transient depression between study visits, they may have been missed. However, if the depression associated with low A β 42/A β 40 is prodromal dementia, we would expect it to be continuously expressed. This was supported by a sensitivity analysis where we examined the association between A β 42/A β 40 and " chronic depression " (those with depression at three or more visits) and found those with a low ratio and APOE e4 allele had a borderline signifi cant increased risk of chronic depression ( odds ratio = 3.00, df = 1, 95% CI: 0.97 -9.26); this association did not exist among those with no APOE e4 ( odds ratio = 0.84, df = 1, 95% CI: 0.41 -1.75). A β 40 and A β 42 were measured at only one time, so we were unable to assess change in A β over time.
Our results suggest that those with low A β 42/A β 40 and at least one APOE e4 allele had an increased risk for depression over 9 years, and these results remained signifi cant even after excluding participants who developed incident dementia. These results suggest that plasma A β 42/A β 40 may be a useful biomarker for depression independent of dementia. These results also support previous hypotheses that plasma A β may be a useful biomarker for a depression subtype representing prodromal dementia. This is of public health signifi cance because of the fast -growing population of older adults who are at an increased risk for both depression and dementia, and the large number of older adults that depression and dementia already affect ( 30 , 31 ) . Future studies are needed to determine how the level of plasma A β 40 and A β 42 fl uctuate over time and how this fl uctuation is associated with depression and dementia, in those with and without APOE e4 alleles. This will help elucidate the complex relationships between A β , depression, and dementia. 
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